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Neoadjuvant
Introduction
Vascular Endothelial Growth Factor (VEGF) stimulates angiogenesis by influencing vessel formation through regulation of proliferation, migration and survival of endothelial cells (1) (2) (3) . Blocking VEGF by bevacizumab, a monoclonal antibody, has been proposed to cause inhibition of neovascularization, regression of existing immature micro-vessels, and normalization of abnormal vasculature (4, 5) ; this has consequences for the flux of oxygen, nutrients, metabolites and therapeutic agents, ultimately preventing tumor growth and resulting in tumor shrinkage. However, addition of bevacizumab to standard chemotherapy in unselected breast cancer patients has resulted only in a modest increase in response rate and progression free survival (6) (7) (8) (9) (10) (11) .
A more in-depth exploration of the effects of angiogenesis blocking agents is important for future efforts to improve patient survival. The effect on the molecular level of bevacizumab administered in combination with chemotherapy has been less studied, and there is a lack of biomarkers for prediction of tumor responsiveness to bevacizumab (12) . Breast cancer is a heterogeneous disease with at least five subtypes according to the PAM50 classification, each with distinct biology and clinical outcome (13) (14) (15) . The frequency and prognostic impact of pathological complete response are known to vary between PAM50 subtypes (16) (17) (18) (19) . Subtype-specific responses to bevacizumab have not yet been systematically studied. Stratification of patients by molecular subtype may be important to identify patient subpopulations that will benefit from such treatment.
In this study, the effect of bevacizumab in HER2-negative breast carcinomas treated with a neoadjuvant chemotherapy regimen is investigated by comparing gene expression profiles of responding and non-responding tumors. Tumors were also compared before, during and after treatment in a subtype-and treatment-specific manner, to reveal molecular changes influenced by the therapy.
Patients and methods

Study design
Patients were recruited at two sites in Norway (Oslo University Hospital, Oslo and St.
Olav's Hospital, Trondheim), between November 2008 and July 2012. Written informed consents were obtained from all patients prior to inclusion. The study was approved by the institutional protocol review board, the regional ethics committee, the Norwegian Medicines Agency and carried out in accordance with the Declaration of Helsinki, International Conference on Harmony/Good Clinical practice. The study is registered in the http://www.ClinicalTrials.gov/ database with the identifier NCT00773695.
Patients with HER2-negative mammary carcinomas with size ≥ 2.5 cm previously untreated for breast cancer were eligible. Other key inclusion criteria were WHO performance status ≤ 2, adequate hematological and biochemical parameters, and no sign of metastatic disease. Additional prerequisites were normal organ function in general and normal left ventricular ejection fraction. Concomitant medications with anticoagulants, other than low dose acetylsalicylic acid (160 mg or lower) were not allowed. A block randomization procedure was used, and the randomization was performed by the centralized research support facility at Oslo University Hospital. The randomization list was not known to the personnel responsible for providing information or treatment to the patients. The patients were stratified based on their tumor size (2.5 ≤ T ≤ 5 cm, T > 5 cm) and hormone receptor status (positive for estrogen (ER), progesterone, or both), and randomized 1:1 to receive bevacizumab and chemotherapy (combination-therapy arm) or chemotherapy alone (chemotherapy arm).
Of the 150 patients enrolled, 138 were assigned to treatment with chemotherapy, and 12 (independently randomized; not reported herein) received endocrine therapy as determined by the responsible oncologist. Of the 138 patients treated with chemotherapy, 66 in each group were included in the primary efficacy analysis (Figure   1 ).
Treatment
The chemotherapy regimen consisted of 4 cycles of FEC100 (5-fluorouracil 600 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 600 mg/m2) every 3 weeks, followed by docetaxel 100 mg/m2 every 3 weeks or 12 weekly infusions of paclitaxel 80 mg/m2.
Bevacizumab was administered intravenously at a dose of 15 mg/kg every third week or 10 mg/kg every other week in patients receiving docetaxel or paclitaxel, respectively.
Tumor evaluation, sampling and assessment of response
Hematological parameters were evaluated before each chemotherapy administration, whereas biochemical parameters were evaluated every third week. The local pathologist, blinded to the treatment assignment, performed histopathological examination of the breast using study-specific guidelines.
Samples were sequentially collected before treatment (core needle biopsies; termed 'week 0 samples'; n = 132), during treatment (core needle biopsies 12 weeks into treatment and minimum three weeks after the last FEC dose; termed 'week 12 samples'; n = 115) and after treatment (at surgery, minimum three weeks after the last taxane dose; termed 'week 25 samples'; n = 112). Altogether 358 specimens were available for further analyses. Matched tumor samples from all three time points were available from 96 patients.
Pathological complete response (pCR), herein defined as complete eradication of all invasive cancer cells in both breast and axillary lymph nodes, was the primary end point.
Gene expression profiling
Gene expression profiling was performed using 40ng total RNA and one color Sureprint The PAM50 subtyping algorithm developed by Parker et al. 2009 (14) was used to assign a subtype label to each sample (details in data supplement). A proliferation score was derived for each sample by computing mean expression values of 11 proliferation related PAM50 genes: CCNB1, UBE2C, BIRC5, KNTC2, CDC20, PTTG1, RRM2, MKI67, TYMS, CEP55, and CDCA1 14 . TP53 mutation status was determined by sequencing the entire coding region (exons 2-11), including splice junctions (details in data supplement).
Statistics
All statistical analyses were performed in R version 3.0. 3 (20) . Associations between variables were assessed with Fisher's exact tests, t-tests and Kruskal-Wallis tests as appropriate. Significance Analysis of Microarrays (SAM) was used to find differentially expressed genes (DEGs) between two groups using the R package samr (21,22) and reporting genes called significant at False Discovery Rate (FDR) 5%. Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used for enrichment analysis on the DEGs. A measure of KEGG pathways activity was obtained using the R package qusage (23).
Results
Patient and tumor characteristics
The study overview is presented in Figure 1 . Demographic characteristics were balanced between the treatment arms ( Table 1) . No significant skewness in distribution of important clinical and molecular parameters such as tumor size, grade, lymph node status, hormone receptor status, TP53 mutation status or PAM50 subtypes (Fisher's exact test and χ 2-test) was observed; neither were any genes differentially expressed in the pre-treatment biopsies between the treatment arms (two-class unpaired SAM).
Febrile neutropenia, proteinuria and hypertension were the most frequent adverse events observed in both treatment arms ( Table 2 ). In the combination-therapy arm, significantly higher frequencies of bleeding disorders and hypertension were observed (Fisher's Exact test; P < 0.001). Serious adverse events, mainly febrile neutropenia and infection were also significantly more frequent in this arm (Fisher's Exact test; P < 0.001 and P < 0.05, respectively). One death occurred after 12 weeks in the combinationtherapy arm, but despite autopsy, a specific cause could not be established. Comparing tumor gene expression profiles before treatment in the combination-therapy arm in patients that achieved pCR (n = 15) to those that did not (n = 51) identified 720 differentially expressed genes (DEGs; two-class unpaired SAM; Table S1 ). Functional annotation analyses of these genes using DAVID (24) (Table S2) .
Similar analyses in the chemotherapy only arm identified 1243 DEGs between the complete responders (n = 8) and the non-complete responders (n = 57) (two-class unpaired SAM; Table S3 ). The gene-list was modestly enriched for genes involved in cell-cycle related processes and included GO terms such as chromatin, nucleus and chromosomal part, cell division and nuclear chromosome segregation (DAVID ; Table   S4 ). A total of 173 DEGs (24% of DEGs in the combination-therapy arm) between the complete responders and non-complete responders overlapped among the two treatment arms, and were enriched for genes involved in DNA damage and repair, and cell-cycle processes.
The gene expression of the DEGs was further correlated with the continuous response ratio (ratio of tumor size at start of treatment to size at surgery). In the ER positive subset of the combination-therapy arm, 345 out of 720 DEGs remained after correction for multiple testing (Spearman's correlation test, FDR <0.05); the gene-list was highly enriched for genes involved in immune processes. In the ER positive subset of the chemotherapy arm, only one out of 1243 DEGs remained significant after multiple testing correction (FDR < 0.05).
Tumors treated with bevacizumab exhibit accelerated reduction in proliferation score
We next evaluated whether gene expression profiles were differently affected by the two treatment regimes. The week 12 samples in the combination-therapy arm showed significant lower expression of 42 genes compared to the chemotherapy arm (two-class unpaired SAM; Table S5 ). The gene list was highly enriched for genes involved in cellcycle related and cellular components maintaining pathways (DAVID ; Table S6 ). Thus, at week 12, cell-cycle related processes were significantly more suppressed in the combination-therapy arm. An overall decrease in PAM50 proliferation score (14) was observed in both treatment arms over time (Kruskal-Wallis test, p < 0.001; Figure S1 ).
Notably at week 12, the proliferation score was significantly lower in the combinationtherapy arm compared to the chemotherapy arm (Kruskal-Wallis test, p = 0.006; Figure   3A ). Stratification by ER-status showed a similar, but more pronounced downregulation of cell-cycle genes at week 12 in the ER-positive subset of the combinationtherapy arm, with correspondingly larger difference in proliferation score between treatment arms (Kruskal-Wallis test, P = 0.001). In the ER negative subset, no significant differences in gene expression profiles were detected between the treatment arms at any time point. Figure 4A and Table S10; Figure 4B and Table S11; Figure 4C and Table S12 ).
Pathway activity analyses performed using 186 pathways in the KEGG database revealed that corresponding to the highest numbers of genes affected in Luminal-B tumors, several pathways showed significantly lower activity in the combination arm compared to the chemotherapy arm. Pathways involved in DNA replication and repair, cell cycle, RNA degradation, purine and pyrimidine metabolism were among the top hits.
( Figure 4D ; Table S13 ). For Luminal-A and Basal-like subgroups, fewer pathways showed significantly differential activity between the two treatment arms. Figure 4C) . A subsequent pathway activity analysis showed significant differences in pathway activity between the two treatment regimens for around 100 pathways, including retinol metabolism, PPAR signaling, ribosome and spliceosome synthesis, cell-cycle and DNA repair pathways ( Figure S2 ; Table S14 ).
Changes in response to
Corresponding to few/none DEGs in Basal-like and Luminal-B subgroup after taxane treatment, no significant differences in pathway activities were detected between week
Discussion
In this study, transcriptional response to treatment with standard chemotherapy, with and without bevacizumab was studied in serial biopsies from 132 patients. More patients achieved pCR in the combination-therapy arm compared to the chemotherapy alone arm, in line with reports from previous studies (6, 7, 10, 11) . A significant benefit of adding bevacizumab was observed in the ER-positive subgroup consistent with the larger NSAPB-B40 trial (11) , in contradiction to the GeparQuinto trial, where the ERnegative tumors were found to benefit from bevacizumab (10) , and the CALGB40603 study, including patients with a low ER expression, or triple negative tumors (6) . The clinical toxicity increased with bevacizumab treatment, as more patients experienced febrile neutropenia in addition to hypertension and episodes of bleeding.
Increases in febrile neutropenia and hypertension have also been seen in similar studies (10, 11) . The clinical practice guidelines at the time of the study were not recommending the use of G-CSF for all patients, only those having experienced febrile neutropenia, and this may have increased the frequency of this adverse event.
In this study, immune response was found to be a strong predictor of response in patients treated with bevacizumab in addition to the standard chemotherapy. The effect of addition of bevacizumab at gene expression level was most evident in the ER-positive Luminal-B tumors. In conclusion, the study provides valuable insights into changes in tumor behavior after neoadjuvant chemotherapy with and without bevacizumab, which may aid in identifying patients more likely to benefit from addition of bevacizumab to the standard chemotherapy. Mean difference in pathway pathway acitivity in the combination therapy arm from week0 to week12 Mean difference in pathway pathway acitivity in the chemotherapy arm from week0 to week12
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